Company’s 36-month beta value is 0.90.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 4 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for BCYC is 65.84M, and currently, short sellers hold a 4.02% ratio of that floaft. The average trading volume of BCYC on October 17, 2024 was 355.45K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BCYC) stock’s latest price update
Bicycle Therapeutics Plc ADR (NASDAQ: BCYC)’s stock price has gone decline by -1.49 in comparison to its previous close of 27.51, however, the company has experienced a 8.23% increase in its stock price over the last five trading days. businesswire.com reported 2024-10-16 that CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present data highlighting its potential to develop differentiated radiopharmaceutical molecules, called Bicycle Radionuclide Conjugates (BRC®), at the European Association of Nuclear Medicine (EANM) 2024 Congress taking place.
BCYC’s Market Performance
BCYC’s stock has risen by 8.23% in the past week, with a monthly rise of 11.25% and a quarterly rise of 21.36%. The volatility ratio for the week is 6.64% while the volatility levels for the last 30 days are 5.89% for Bicycle Therapeutics Plc ADR The simple moving average for the past 20 days is 11.19% for BCYC’s stock, with a 20.47% simple moving average for the past 200 days.
Analysts’ Opinion of BCYC
Many brokerage firms have already submitted their reports for BCYC stocks, with RBC Capital Mkts repeating the rating for BCYC by listing it as a “Outperform.” The predicted price for BCYC in the upcoming period, according to RBC Capital Mkts is $35 based on the research report published on September 06, 2024 of the current year 2024.
B. Riley Securities, on the other hand, stated in their research note that they expect to see BCYC reach a price target of $28, previously predicting the price at $33. The rating they have provided for BCYC stocks is “Neutral” according to the report published on August 07th, 2024.
BCYC Trading at 14.24% from the 50-Day Moving Average
After a stumble in the market that brought BCYC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.48% of loss for the given period.
Volatility was left at 5.89%, however, over the last 30 days, the volatility rate increased by 6.64%, as shares surge +6.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.51% upper at present.
During the last 5 trading sessions, BCYC rose by +8.53%, which changed the moving average for the period of 200-days by +47.37% in comparison to the 20-day moving average, which settled at $24.38. In addition, Bicycle Therapeutics Plc ADR saw 49.89% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCYC starting from Lee Kevin, who sale 3,212 shares at the price of $22.26 back on Oct 03 ’24. After this action, Lee Kevin now owns 380,864 shares of Bicycle Therapeutics Plc ADR, valued at $71,499 using the latest closing price.
Hannay Michael Charles Ferguso, the CHIEF PROD & SUPPLY CHAIN OFF of Bicycle Therapeutics Plc ADR, sale 247 shares at $22.26 during a trade that took place back on Oct 03 ’24, which means that Hannay Michael Charles Ferguso is holding 22,398 shares at $5,498 based on the most recent closing price.
Stock Fundamentals for BCYC
Current profitability levels for the company are sitting at:
- -5.22 for the present operating margin
- 0.83 for the gross margin
The net margin for Bicycle Therapeutics Plc ADR stands at -4.18. The total capital return value is set at -0.21. Equity return is now at value -30.27, with -21.90 for asset returns.
Based on Bicycle Therapeutics Plc ADR (BCYC), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -4.55. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -63.01.
Currently, EBITDA for the company is -168.8 million with net debt to EBITDA at 4.86. When we switch over and look at the enterprise to sales, we see a ratio of 23.98. The receivables turnover for the company is 0.85for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.77.
Conclusion
In a nutshell, Bicycle Therapeutics Plc ADR (BCYC) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
